Documentation of thyroid function in clinical studies with sunitinib: Why does it matter?

Journal of Clinical Oncology

Volumn 26, Issue 31, 2008, Pages 5131-5132

  Garfield, David H ^a   Wolter, Pascal ^b   Schöffski, Patrick ^b   Hercbergs, Aleck ^c   Davis, Paul ^d  

^a UNIVERSITY OF COLORADO CANCER CENTER   (United States)

^b UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^c LERNER RESEARCH INSTITUTE   (United States)

^d ORDWAY RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DRUG METABOLITE; INTERLEUKIN 2; PROPYLTHIOURACIL; SU 12662; SUNITINIB; THYROID HORMONE; THYROTROPIN; UNCLASSIFIED DRUG; VITRONECTIN RECEPTOR;

ASTHENIA; BREAST METASTASIS; CLINICAL TRIAL; COLORECTAL CANCER; CONSTIPATION; DISEASE FREE SURVIVAL; DRY SKIN; FATIGUE; HEAD AND NECK CANCER; HORMONE SUBSTITUTION; HUMAN; HYPOTHYROIDISM; KIDNEY CARCINOMA; LETTER; LUNG NON SMALL CELL CANCER; METASTASIS; NONHUMAN; PLASMA CONCENTRATION-TIME CURVE; PRIORITY JOURNAL; THYROID FUNCTION; THYROTROPIN BLOOD LEVEL;

ANGIOGENESIS INHIBITORS; FEMALE; HUMANS; HYPOTHYROIDISM; INDOLES; MALE; NEOPLASMS; PYRROLES; THYROID FUNCTION TESTS; TREATMENT OUTCOME;

EID: 55549092771     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2008.18.8680     Document Type: Letter

References (30)

1. Saltz LB, Rosen LS, Marshal JL, et al: Phase II trials of sunitinib in patients with metastatic colorectal cancer after failure of standard therapy. J Clin Oncol 25:4793-4799, 2007
2. Socinski MA, Novello S, Brahmer JR, et al: Multicenter, phase II trial of sunitinib in previously treated, advanced non-small-cell lung cancer. J Clin Oncol 26:650-656, 2008
3. Burstein HJ, Elias AD, Rugo HS, et al: Phase II study of sunitinib malate, an oral multitargeted tyrosine kinase inhibitor, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane. J Clin Oncol 26:1810-1816, 2008
4. Demetri GD, van Oosterom AT, Garrett CR, et al: Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: A randomised controlled trial. Lancet 368:1329-1338, 2006
5. Motzer RJ, Michaelson MD, Redman BG, et al: Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. J Clin Oncol 24:16-24, 2006
6. Motzer RJ, Hutson TE, Tomczak P, et al: Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 356(2):115-124, 2007
7. Rini BI, Tamaskar I, Shaheen P, et al: Hypothyroidism in patients with metastatic renal cell carcinoma treated with sunitinib. J Natl Cancer Inst 99:81-83, 2007
8. Desai J, Yassa L, Marqusee E, et al: Hypothyroidism after sunitinib treatment for patients with gastrointestinal stromal tumors. Ann Intern Med 145:660-664, 2006
9. Rini BI, Tamaskar I, Shaheen P, et al: Hypothyroidism in patients with metastatic renal cell carcinoma treated with Sunitinib. J Natl Cancer Inst 99:81-83, 2007
10. Wolter P, Stefan C, Decallonne B, et al: The clinical implications of sunitinib-induced hypothyroidism: A prospective evaluation. Br J Cancer (in press)
11. Wong E, Rosen LS, Mulay M, et al: Sunitinib induces hypothyroidism in advanced cancer patients and may inhibit thyroid peroxidase activity. Thyroid 17:351-355, 2007
12. Mannavola D, Coco P, Vannucchi G, et al: A novel tyrosinekKinase selective inhibitor, sunitinib, induces transient hypothyroidism by blocking iodine uptake. J Clin Endocrinol Metab 92:3531-3534, 2007
13. Wolter P, Stefan C, Decallonne B, et al: Evaluation of thyroid dysfunction as a candidate surrogate marker for efficacy of sunitinib in patients (pts) with advanced renal cell carcinoma (RCC). J Clin Oncol 26:280s, 2008 (suppl; abstr 5126)
14. Houk BE, Bello CL, Michaelson MD, et al: Exposure-response of sunitinib in metastatic renal cell carcinoma (mRCC): A population pharmacokinetic/ pharmacodynamic (PKPD) approach. J Clin Oncol 25:241s, 2007 (suppl; abstr 5027)
15. Garfield DH, Hercbergs A, Davis P: Management issues in the hypothyroidism developing in cancer patients treated with sunitinib and other multitargeted tyrosine kinase inhibitors. Nat Clin Pract Oncol 4:674, 2007
16. Garfield DH, Hercberg A, Davis P: The management of hypothyroidism after radiotherapy for nasopharyngeal carcinoma. Med Oncol 2008 Apr 30; [epub ahead of print on April 30, 2008]
17. Garfield DH, Hercbergs A: Fewer dollars, more sense. J Clin Oncol (in press)
18. Davis FB, Tang H-Y, Shih A, et al: Acting via cell surface receptor, thyroid hormone is a growth factor for glioma cells. Cancer Res 66:7270-7275, 2006
19. Davis PJ, Davis FB, Lin H-Y, et al: Cell surface receptor for thyroid hormone and tumor cell proliferation. Expert Rev Endocrin Metab 1:753-761, 2006
20. Davis PJ, Leonard JL, Davis FB: Mechanisms of nongenomic actions of thyroid hormone. Front Neuroendocrinol 29:211-218, 2008
21. Theodossiou C, Skrepnik N, Robert EG, et al: Propylthiouracil-induced hypothyroidism reduces xenograft tumor growth in athymic nude mice. Cancer 86:1596-1601, 1999
22. Mishkin SY, Pollack R, Yalovsky MA, et al: Inhibition of local and metastatic hepatoma growth and prolongation of survival after induction of hypothyroidism. Cancer Res 41:3040-3045, 1981
23. Kumar MS, Chiang T, Deodhar SD: Enhancing effect of thyroxine on tumor growth and metastases in syngeneic mouse tumor systems. Cancer Res 39:3515-3518, 1979
24. Shoemaker JP, Bradley RL, Hoffman RV: Increased survival and inhibition of mammary tumors in hypothyroid mice. J Surg Res 21:151-154, 1976
25. Nelson M, Hercbergs A, Rybicki L, et al: Association between development of hypothyroidism and improved survival in patients with head and neck cancer. Arch Otolaryngol Head Neck Surg 132:1041-1046, 2006
26. Hercbergs A, Suh JH, Lee S, et al: Propylthiouracil-induced chemical hypothyroidism with high dose tamoxifen prolongs survival with increased response rate in recurrent high-grade gliomas. Anticancer Res 23:617-626, 2003
27. Hercbergs A, Suh J, Reddy C, et al: Early onset propylthiouracil-induced hypothyroidism is associated with improved survival in recurrent high grade glioma. Am Assoc Cancer Res Proceed 49:2008 (abstr 1211)
28. Cristofanilli M, Yamamura Y, Kau SW, et al: Thyroid hormone and breast carcinoma: Primary hypothyroidism is associated with a reduced incidence of primary breast carcinoma. Cancer 103:1122-1128, 2005
29. Weijl NI, Van der Harst D, Brand A, et al: Hypothyroidism during immunotherapy with interleukin-2 is associated with antithyroid antibodies and response to treatment. J Clin Oncol 11:1376-1383, 1993
30. Surks ML, Ortiz E, Daniels GH, et al: Subclinical thyroid disease. JAMA 291:228-238, 2004